Black and Hispanic patients who received chimeric antigen receptor T-cell therapy for relapsed or refractory non-Hodgkin lymphoma achieved similar efficacy outcomes as white and Asian individuals, according to study results.
Similar treatment-related toxicities occurred regardless of patients’ race or ethnicity, findings published in Bone Marrow Transplantation showed.
An analysis to determine possible associations between race/ethnicity and CAR-T outcomes is long overdue, according to Mendel Goldfinger, MD, assistant professor of medicine at Albert Einstein College of Medicine and member